|
2018 |
| • SINOMED Group completed the Shareholding System transformation and became a joint-stock company |
| • SINOMED completed the overseas company layout with an overseas operation platform represented by Hong Kong, US, Japan, and European subsidiaries. |
| • BASIS study which is the world’s first clinical study comparing intracranial balloon dilatation and medication was launched in China. |
|
2017 |
| • MACH2™, Bravo™ and Sleek Prime™ Balloon Catheters receives CE mark. |
| • BuMA™ DES registered in Brazil and Kazakhstan. |
| • MACH2™, Bravo™ Balloon Catheter registered in Thailand. |
|
2016 |
| • BuMA™ DES registered in Indonesia and Thailand. |
| • Sleek Prime ™ PTCA Balloon Catheter registered in South Korea. |
|
2015 |
| • BuMA™ DES, Bravo™ NC Balloon Catheter distributed to Pakistan. |
|
2014 |
| • Sleek™ PTCA Balloon Catheter distributed to Indonesia. |
|
2013 |
| • SUN™ Bare Metal Stent receives CE mark. |
| • SUN™ Bare Metal Stent, Sleek™ PTCA Balloon Catheter distributed to Malaysia. |
|
2012 |
| • SINOMED aquires patent for eG™ coating technology. |
| • BuMA™ DES receives worldwide IP. |
| • Sleek™ PTCA Balloon Catheter Distributed to Turkey and Iran. |
|
2010 |
| • Novel Biodegradable Drug Coating Coronary Stent BuMA™ approved by SFDA. |
|
2008 |
| • Sleek™ PTCA Balloon Catheter receives CE mark. |
|
2007 |
| • SINOMED established in China. |
|
2002 |
| • Sleek™ PTCA Balloon Catheter and SUN™ Bare Metal Stent approved by SFDA. |
|
2001 |
| • Beijing Sun Technology Inc. (prior entity of SINOMED) establishes in China. |
